James T. England

Physician and Clinician Investigator focused on Leukemia & Myeloproliferative Neoplasms.

[Anastasia Tikhonova @DrStass]

What happens to the bone marrow niche in #CHIP? We find that CHIP is associated with fibro-inflammatory hubs emerging before the disease.
Co-led by our fantastic @aliciaguilar_ and @gibran_edun
https://t.co/sdGAgbKBG0
#ClonalHematopoiesis #PreTumorMicroenvironment #Hematopoiesis

[Princess Margaret Cancer Centre Research @PMResearch_UHN]

In people with age-related blood stem cell mutations, our study found early pre-fibrosis and inflammatory regions in the bone marrow, that may set the stage for blood cancer development.

The @NatImmunol study was led by @DrStass @UHN @pmcancercentre:
https://t.co/7iMeR2AW5q

[Talha Badar @TalhaBadarMD]

Venetoclax plus pediatric regimen in adolescents and adults with Ph-negative acute lymphoblastic leukemia https://t.co/F0gAhRyCA2

Promising phase II data for frontline venetoclax + pediatric-inspired chemotherapy in 167 pts age 14–60 with newly diagnosed Ph-negative ALL: CR 91%, post-induction MFC-MRD negativity 73% among responders, 2-year OS 78.5% and DFS 76.7%. Toxicities were mainly hematologic/infectious. Encouraging depth of response, but single-arm design, historical comparator, and short follow-up mean randomized validation is still needed. #ALL #Leusm. @BloodPortfolio

[Talha Badar @TalhaBadarMD]

1/10 #weekend_review #mdssm HIGHER-RISK #MDS: A DECADE OF CLINICAL TRIALS

The last decade in HR-MDS has taught us a humbling lesson:

Promising biology ≠ successful phase III trial.
Higher response rate ≠ longer survival.

Here is 🧵 on the trials that shaped the field, why so many failed, and where we go next. 👇

[Lisa Palacios @Lisa_Palacios]

Friday, Sept 11
At #SOHO2026, @danielleHammo20 breaks down #VEXAS Syndrome—an emerging hematologic and inflammatory disorder with rapidly evolving research and treatment approaches. @UTMDAnderson Booth #110
🔗 Schedule: https://t.co/kqcJ9cepEs @SocietyofHemOnc

[Anastasia Tikhonova @DrStass]

What happens to the bone marrow after chemotherapy?
Very excited to share our new paper, featured on the cover of @BloodPortfolio, led by an incredibly talented student in my lab, Ximing Li! 🎉
https://t.co/SZHwoxkHF4

[Talha Badar @TalhaBadarMD]

1/5 For a decade, decitabine has been assumed superior to azacitidine in TP53-mutant AML based on deeper molecular clearance. We tested that assumption in 652 patients across 15 centers #COMMAND_consortium Thread 🧵 #leusm #AML #TP53 https://t.co/dKCje7lhUD @LeukemiaJnl @Dr_AmerZeidan @Anand_88_Patel @Dr_RoryShallis @ShyamPatelMDPhD @yu_hung_wang @vamkota @yasminabaza1 @AlexColtoff @AyaOncologist @CharlieFoucar @MRLitzow @MKD_BMT @hemant_murthy @ChenyuLinMD et al.

[UChicago Leukemia Program @UChicagoLeuk]

congrats to @Anand_88_Patel @myeloidmalig who are co-authors on a manuscript looking at heart failure in patients with MPNs

https://t.co/rCOkvFuXDO

[Sankalp Arora, MD @sankalparoraMD]

Now out in @Haematologica; Final results of our phase 2 study @UTMDAnderson of Azacitidine-Ruxolitinib combination in #myelofibrosis. These data set the stage for newer HMA-JAKi combinatorial regimens. @Daver_Leukemia @MDmasarova

Link to early view PDF: https://t.co/zjFGrWnhyv

[Shahram Kordasti @SKordasti]

A short trip to Toronto and the Sunnybrook Cancer Centre to start a new collaboration within the i4MDS project and explore the possibility of establishing another i4MDS referral centre in North America.

If all goes according to plan, this could be another important step in expanding the #i4MDS network. More to come soon!

[Orly Leiva, MD FACC @LeivaOrly]

🚨New Pub🚨

HOHF is assoc w MPNs. In this study we characterized pts with ET or PV by TTE cardiac output and PASP. There was an assoc between ⬆️ risk progression to MF or leukemia among those with HOHF compared to normal hemodynamics.
#CardioOnc #MPNsm

https://t.co/iHGa7Py5QQ

[Novi Yanti Sari @slumberbell]

Beyond thrombosis: what cardiovascular complications should we look for in patients with #MPN?🫀

This review highlights that the #CV burden extends beyond arterial & venous thrombosis:
📍#HF may be more prevalent in MPNs than in general population, with worse HF-specific outcomes reported in myelofibrosis
📍Traditional CV risk factors are less common in these patients, suggesting a distinct HF phenotype
📍#PH is common & may be pre-capillary, post-capillary or combined, requiring careful haemodynamic evaluation. #EchoFirst is the recommended screening tool, with #RHC for definitive diagnosis
📍PH screening should be considered in patients with myelofibrosis, long-standing #MPN, signs of disease progression & cardiomegaly
📍Emerging data suggest that both HF & PH may be associated with adverse cardiovascular outcomes & hematologic progression in MPN, highlighting potential shared pathophysiology such as chronic inflammation & JAK/STAT pathway activation

Read more in #JACCCardioOnc: 🔗 https://t.co/C693RMQD3g

#CardioOncology #PulmonaryHypertension #HeartFailure

[Talha Badar @TalhaBadarMD]

Blinatumomab moves the needle in frontline high-risk Ph-negative B-#ALL @BloodPortfolio

In the GRAALL-2014/B QUEST study, blinatumomab consolidation:
✅ Higher MRD negativity: 72% vs 54% (P=0.04)
✅ Improved disease-free survival: ~70% vs ~45% at 5 years (P=0.001)
✅ Improved overall survival: ~75% vs ~60% at 5 years (P=0.03)

The remaining question is whether allogeneic HCT is still required for patients with MRD neg after blinatumomab, an area that warrants prospective evaluation.

Congratulations to Boissel and colleagues on this important contribution.

[James T. England @jamesengland0]

@DanielleHammo20 @tarekmd91 so much tp53 selection

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉Proud to share our international randomized frontline Myelofibrosis Ph3 #TRANSFORM-1 final results | #Navitoclax + RUXO | #MPNSM just out in @BloodPortfolio today! 🙏 📝 🚨

@doctorpemm @AdamMead_Oxford @jjkiladjian @sk_tantravahi

https://t.co/FEmAylIrq4

[Joshua Zeidner MD @LeukDocJZ]

Super proud of @beatalleukemia for delivering a fantastic presentation of the OPTI-AML data showing that Aza/Ven-14 is NOT equivalent to Aza/Ven-28 days at least for induction cycles 1-2. Highly impactful study from our BEAT AML team @bcutd_research

[Sangeetha Venugopal MD,MS @drsangeetmd]

@JenMarvinPeek presenting the role of IDH1 triplet in #AML #EHA2026

[Amer Zeidan عامر زيدان @Dr_AmerZeidan]

A moment of pride! A co-first author in the best journal in medicine for a clinical trial that resulted in FDA approval in the USA and is changing how we treat acute myeloid leukemia #AMLsm. Congratulations to all the authors لحظة فخر! باحث أول مشارك في أفضل مجلة علمية في الطب لتجربة إكلينيكية أدت إلى موافقة إدارة الغذاء والدواء الأمريكية وتغير الطريقة التي نعالج بها اللوكيميا النخاعية الحادة.

[Talha Badar @TalhaBadarMD]

#ASCO26 #leusm #AML

Triplet therapy with azacitidine + venetoclax + ivosidenib in newly diagnosed, unfit IDH1-mutated AML.

🔹 ORR 95%, CRc 93% (CR 60%)
🔹 Flow MRD negativity in 91% of evaluable responders
🔹 3-year OS 79%
🔹 3-year remission duration 83%
🔹 3-year cumulative incidence of relapse only 9%

Notably, only 3 patients relapsed, all with emergence of IDH1-negative clones, highlighting deep suppression of the target clone but potential evolution of alternative leukemic populations.

[James T. England @jamesengland0]

@Papa_Heme Seen it in a patient with undiagnosed celiac disease....pancytopenias improve but the neuropathy...